Lapatinib Recruiting Phase 2 Trials for HER2 Positive Breast Cancers Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02362958A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer